Accessibility StatementSkip Navigation MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ --Â Boston Scientific Corporation (NYSE:Â BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational basis and 15.3 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 m ...

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - Boston Scientific is a rapidly growing leading platform company in the medical device sector, with a projected total market size of $70 billion across its eight segments by 2025 [3] - The main growth drivers are the electrophysiology and left atrial appendage closure businesses, with electrophysiology expected to see significant growth starting in 2024 [3] - The electrophysiology market is projected to reach $10 billion in 2024, with a growth rate of 15%-20% in the following years [11] Summary by Sections Electrophysiology: Rapid Growth and Market Leadership - Electrophysiology is expected to become a global leader, with Boston Scientific leveraging disruptive technology to gain market share [5][10] - The company anticipates a revenue of $1.9 billion from electrophysiology in 2024, representing a 138% year-over-year increase [55] - The PFA (Pulsed Field Ablation) technology is rapidly gaining traction, expected to capture 20% of the atrial fibrillation ablation market in 2024 and potentially double by 2025 [3][11] Left Atrial Appendage Closure: Industry Leadership and Progress - Boston Scientific holds approximately 90% market share in left atrial appendage closure in the U.S., making it the absolute leader in this segment [3] - The revenue from left atrial appendage closure is projected to reach $1.5 billion in 2024, with a CAGR of 22% from 2021 to 2024 [3] - The OPTION data readout is expected to catalyze the adoption of left atrial appendage closure as a first-line treatment for stroke prevention in atrial fibrillation patients [3]

Core Insights - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the top medical device stocks to invest in, with TD Cowen reaffirming a Buy rating and a price target of $115 on October 10 [1] - The recent analyst visit to Boston Scientific's headquarters reinforced confidence in the company's outlook, particularly in the context of its latest investor day [1] Group 1: Company Performance and Outlook - Significant advancements were noted in pulsed field ablation (PFA) technology during the analyst visit, with feedback suggesting a "very compelling" outlook for Boston Scientific despite increasing market competition [2] - CEO Mike Mahoney provided thoughtful responses to growth-related inquiries, emphasizing category leadership as a strategy for achieving success in the market [2] Group 2: Company Profile - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [3]

Core Viewpoint - Boston Scientific Corporation is positioned for growth with expected increases in earnings and revenue, despite a slight downward revision in EPS estimates [2][3][6] Financial Performance - The company is projected to report an earnings per share (EPS) of $0.71, reflecting a 12.7% increase year-over-year [2][6] - Revenue is anticipated to reach approximately $4.97 billion, marking an 18% rise compared to the same period last year [2][6] - Boston Scientific has a history of exceeding earnings expectations, with an average surprise of 8.11% over the past four quarters [4] Market Position and Innovations - The company specializes in a wide range of medical devices for interventional specialties, with key innovations like the WATCHMAN FLX Pro and AGENT DCB enhancing its market position [1] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 59.41, indicating a high valuation relative to earnings [5][6] - A debt-to-equity ratio of 0.54 suggests a moderate level of debt relative to equity [5][6] - The current ratio of about 1.37 indicates reasonable liquidity to cover short-term liabilities [5]

Core Insights - Boston Scientific announced the acquisition of Nalu Medical for approximately $530 million, marking a significant move in the chronic pain treatment sector [2][3] - The acquisition is expected to enhance Boston Scientific's product line in pain management, integrating Nalu's innovative wireless peripheral nerve stimulation system [5][10] Group 1: Acquisition Details - The acquisition will complete Boston Scientific's strategic investment in Nalu, which began in 2017, and is expected to finalize in the first half of 2026 [3] - Nalu is projected to exceed $60 million in sales by 2025, with a growth rate of over 25% in 2026 [3] Group 2: Strategic Implications - This transaction represents a strategic shift from "central control" to "peripheral control," broadening Boston Scientific's coverage in pain management from deep to peripheral nerve solutions [5] - The acquisition positions Boston Scientific competitively against major players like Medtronic and Abbott in the neuromodulation market [5] Group 3: Nalu's Growth and Technology - Prior to the acquisition, Nalu secured $50 million in growth capital from Trinity Capital, indicating its readiness for commercialization and expansion [6] - Nalu's Neurostimulation System is a battery-free, miniaturized, wireless device that simplifies surgical procedures and reduces maintenance costs [8] Group 4: Clinical Efficacy - Clinical trials demonstrated that Nalu's system achieved over 50% pain relief in 87% and 79% of patients in two randomized controlled studies, with an average pain reduction of 64% [9] - The system's design enhances patient compliance and post-operative experience, making it a viable alternative to traditional pain management methods [9] Group 5: Market Context - Chronic pain affects over 1 billion people globally, with traditional treatments posing risks of dependency and abuse [10] - The market is currently dominated by Medtronic, Abbott, and Boston Scientific, which together hold about 80% market share, but Nalu's innovative approach offers a differentiated solution [10] Group 6: Future Outlook - The acquisition signals a shift in the neuromodulation market towards simpler, more accessible technologies that can be widely adopted in clinical settings [11][12] - The focus is moving from complex systems to lightweight, replicable technology models, indicating a potential turning point for peripheral nerve stimulation [11][12]

Group 1: Market Sentiment and Trading Activity - Financial giants have shown a bearish sentiment towards Boston Scientific, with 48% of traders exhibiting bearish tendencies compared to 44% bullish [1] - The analysis of options trading revealed 25 unusual trades, with a total value of $1,728,675, where 4 were puts valued at $272,710 and 21 were calls valued at $1,455,965 [1] - The major market movers are focusing on a price range between $95.0 and $105.0 for Boston Scientific over the last three months [2] Group 2: Options Volume and Open Interest - The mean open interest for Boston Scientific options trades is 4,139.8, with a total volume of 23,825.00 [3] - A detailed analysis of the last 30 days shows significant trading activity within the strike price range of $95.0 to $105.0 [3][4] Group 3: Company Overview - Boston Scientific specializes in less invasive medical devices used in various medical fields, including angioplasty, cardiac rhythm management, and interventional oncology [9][10] - Approximately 36% of Boston Scientific's total sales come from foreign markets [10] Group 4: Analyst Ratings and Price Targets - Five market experts have issued ratings for Boston Scientific, with a consensus target price of $124.0 [11] - Analysts from Needham, Canaccord Genuity, Truist Securities, Leerink Partners, and Evercore ISI Group have set price targets ranging from $110 to $132, maintaining a Buy or Outperform rating [12] Group 5: Current Stock Performance - The current stock price of Boston Scientific (BSX) is $98.29, reflecting a 0.52% increase with a trading volume of 3,885,070 [14] - RSI indicators suggest that the stock may be approaching overbought conditions [14]

Core Viewpoint - Boston Scientific is acquiring the remaining equity in Nalu Medical for approximately $533 million in cash, enhancing its chronic pain treatment portfolio [1][2] Group 1: Acquisition Details - The acquisition provides Boston Scientific access to Nalu's neurostimulation device, which utilizes peripheral nerve stimulation (PNS) for targeted pain relief [1][3] - This year, Boston Scientific has made several acquisitions, including a $443 million payment for Bolt Medical [2] - The deal is expected to be immaterial to Boston Scientific's adjusted profit in 2026 but slightly accretive in 2027, with increasing benefits thereafter [5] Group 2: Product and Market Insights - Nalu's therapy employs mild electrical impulses to disrupt pain signals before they reach the brain and features a miniaturized, battery-free implant powered wirelessly [3] - The device received FDA clearance for PNS in 2019 and for spinal cord stimulation (SCS) in 2020 [4] - Analysts note that Nalu's PNS system is more robust compared to competitors, indicating potential market share gains, while expectations for SCS are more conservative due to Boston's existing offerings [4] Group 3: Market Reaction - Following the announcement, shares of Boston Scientific rose approximately 1% in early trading [5]

Core Viewpoint - Analysts forecast Boston Scientific (BSX) will report quarterly earnings of $0.71 per share, reflecting a year-over-year increase of 12.7%, with revenues expected to reach $4.97 billion, an 18% increase compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts project 'Net Sales- MedSurg- Worldwide' at $1.70 billion, a 15% increase year-over-year [5]. - 'Net Sales- Cardiovascular- Worldwide' is expected to reach $3.27 billion, indicating a 19.7% year-over-year change [5]. - 'Net Sales- Cardiovascular- Cardiology- Worldwide' is estimated at $2.57 billion, reflecting a 20.9% increase from the prior year [5]. - 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' is projected to be $697.63 million, a 15.9% increase year-over-year [6]. - 'Geographic Revenue- Rest of the World' is expected to be $1.76 billion, indicating a 9.1% year-over-year change [6]. - 'Geographic Revenue- U.S.' is projected at $3.21 billion, reflecting a 23.8% increase from the previous year [7]. Additional Sales Projections - 'Net Sales- Cardiovascular- Peripheral Interventions- International' is expected to reach $304.52 million, a 6.9% increase year-over-year [7]. - 'Net Sales- MedSurg- Neuromodulation- United States' is projected at $218.50 million, indicating a 3.6% increase [8]. - 'Net Sales- MedSurg- Neuromodulation- International' is expected to be $62.26 million, reflecting a 9.2% year-over-year change [8]. - 'Net Sales- MedSurg- Endoscopy- United States' is projected at $447.24 million, a 7.3% increase from the prior year [8]. - 'Net Sales- MedSurg- Endoscopy- International' is expected to reach $280.01 million, indicating a 7.3% increase year-over-year [9]. - 'Net Sales- MedSurg- Urology- United States' is forecasted to be $518.55 million, reflecting a significant 36.8% year-over-year change [9]. Stock Performance - Boston Scientific shares have changed by -0.5% in the past month, compared to a +0.7% move of the Zacks S&P 500 composite, with a Zacks Rank 2 (Buy) indicating expected outperformance in the near future [10].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Viewpoint - Boston Scientific is acquiring Nalu Medical for approximately $533 million in cash, which will enhance its offerings in the chronic pain management sector [1] Company Summary - The acquisition of Nalu Medical will allow Boston Scientific to expand its product portfolio specifically targeting chronic pain [1] - The cash payment for the acquisition is reported to be around $533 million, indicating a significant investment by Boston Scientific in this area [1] Industry Summary - This acquisition reflects a growing trend in the medical device industry towards addressing chronic pain, which is a major health concern for many patients [1] - By integrating Nalu Medical's technologies, Boston Scientific aims to strengthen its position in the competitive landscape of pain management solutions [1]